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Asthma is caused by a combination of poorly understood genetic
and environmental factors1,2. We have systematically mapped the
effects of single nucleotide polymorphisms (SNPs) on the presence
of childhood onset asthma by genome-wide association. We char-
acterized more than 317,000 SNPs in DNA from 994 patients with
childhood onset asthma and 1,243 non-asthmatics, using family
and case-referent panels. Here we show multiple markers on chro-
mosome 17q21 to be strongly and reproducibly associated with
childhood onset asthma in family and case-referent panels with a
combined P value of P , 10212. In independent replication studies
the 17q21 locus showed strong association with diagnosis of child-
hood asthma in 2,320 subjects from a cohort of German children
(P 5 0.0003) and in 3,301 subjects from the British 1958 Birth
Cohort (P 5 0.0005). We systematically evaluated the relation-
ships between markers of the 17q21 locus and transcript levels
of genes in Epstein–Barr virus (EBV)-transformed lymphoblastoid
cell lines from children in the asthma family panel used in our
association study. The SNPs associated with childhood asthma
were consistently and strongly associated (P , 10222) in cis with
transcript levels of ORMDL3, a member of a gene family that
encodes transmembrane proteins anchored in the endoplasmic
reticulum3. The results indicate that genetic variants regulating
ORMDL3 expression are determinants of susceptibility to child-
hood asthma.
Our study design aimed to provide internal replication of poten-
tially positive results with family and case-referent panels of subjects
with childhood asthma (Fig. 1). This structure also allowed compar-
ison for consistency between case-control and family-based tests of
association. To systematically investigate the effects of polymorph-
isms on the transcription of positional candidate genes, we further
measured global gene expression in B-cell-derived EBV-transformed
lymphoblastoid cell lines (EBVL) in probands and siblings of the
family panel.
The study subjects included a panel of 207 predominantly (99%)
nuclear families (MRC-A). These were recruited through a proband
with severe (Step 3) childhood onset asthma and contained 295
sib pairs, 11 half-sib pairs and 3 singletons (counting all possible
sibs). Four-hundred and thirty-seven non-asthmatic Caucasian UK
controls (UK-C) were studied by the same protocols. We also geno-
typed 728 children of German origin recruited in the Multicentre
Asthma Genetics in Childhood Study (MAGICS) study with physi-
cian-diagnosed asthma for comparison with 694 reference children
recruited in the cross sectional International Study of Asthma and
Allergies in Childhood (ISAAC) study4.
We genotyped all children in the primary association study with the
Illumina Sentrix HumanHap300 BeadChip. After quality control and
elimination of markers with low minor-allele frequencies (,0.5%),
extreme Hardy–Weinberg equilibrium statistics (x2 . 25) or low
genotyping call rates (,95%), we retained 307,328 SNPs and 684
million genotypes (99.4% call rate) for analysis. Amongst the
2,236,212 common (minimum allele frequency . 0.05) SNPs in the
HapMap panel, 79% were tagged with correlation R2 . 0.8 and 90.9%
with R2 . 0.5 with our successfully typed markers.
We also typed the parents and children in the MRC-A panel with
the Illumina Sentrix Human-1 Genotyping BeadChip (concentrated
on genes and surrounding sequences) (Fig. 1), producing an
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Figure 1 | Study design. The subjects were recruited from family (MRC-A)
and case-control panels (MAGICS and UK-C). All children were genotyped
with the Illumina Sentrix HumanHap300 BeadChip. The children and
parents in the MRC-A panel were in addition genotyped with the Illumina
Sentrix Human-1 Genotyping BeadChip. Gene expression in
lymphoblastoid cell lines (EBVL) was measured in the affected and
unaffected children of the MRC-A panel. Replication of positive results was
sought in two independent panels of subjects from the ISAAC Phase II and
1958 British Birth Cohort studies.
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additional 91,293 SNPs with 36.0% average heterozygosity and
89,815,992 genotypes (99.0% call rate). We found only 0.412 men-
delian errors per SNP: these were excluded from subsequent analyses.
We tested for association of the 300K panel to childhood onset
asthma in the combined primary data set of 994 asthmatics and 1,243
non-asthmatics (Fig. 2). We calculated the 1% false-discovery rate
(FDR) threshold5 to be P # 6.8 3 1027 and the 5% FDR to be
P # 5.0 3 1026. We tested for population stratification in the com-
bined data set, finding a genomic control parameter of 1.07. This
minor degree of background stratification reflected small differences
in allele frequencies within and between the two nationally defined
European populations that contributed to the study.
We further tested the effects of stratification on our top results by
analysing the 34 SNPs that surpassed the 5% FDR threshold with 102
randomly selected SNPs as covariates in a backward stepwise logistic
regression procedure6. The results of the stepwise logistic regression
analysis showed only modest reduction of the support for association
for 31 of the SNPs. Of 34 SNPs, 16 continued to surpass the 5% FDR
and 12 of 20 SNPs remained above the 1% FDR threshold (Sup-
plementary Table 1).
Strikingly, 7 of the 12 markers still below the 1% FDR threshold
mapped to a 112 kb interval on chromosome 17q21. Several other
markers in this interval also showed strong evidence of association
(Supplementary Table 2, Fig. 2 and Fig. 3a). The SNP with the stron-
gest evidence of association within the interval was rs7216389 (uncor-
rected P 5 9 3 10211). With the exception of the 17q21 locus, none
of the markers below the 5% FDR, after controlling for stratification,
were within 1 Mb of each other (Supplementary Table 1).
The patterns of association for the chromosome 17q21 markers
were similar and significant in both the UK family panel and the
German case-referent panel (Table 1 and Supplementary Table 2).
There was no evidence of heterogeneity of the association, or of
significant allele frequency differences in cases or controls from the
UK and Germany.
We selected 27 markers from the NCBI database of genetic vari-
ation (dbSNP) that were within or adjacent to the strongly associated
interval for genotyping. These exhibited similar patterns and
strengths of association as the genome-wide association (GWA) mar-
kers (Supplementary Table 2).
SNPs from the region that we had typed in whole families in the
MRC-A panel showed significant associations in a family-based asso-
ciation test (Supplementary Table 3). The most strongly associated
marker was rs8067378 (248 informative transmissions, P 5 3 3 1026;
odds ratio, 1.84; 95% confidence interval, 1.43–2.42). The pattern of
alleles transmitted in excess to affected offspring was consistent with
the case-referent association results, further indicating that the asso-
ciation was robust to population stratification.
The trait-associated markers (with P , 1026 in the combined data
set) from chromosome 17q21 fall within a 206.5 kb core containing
three consecutive haplotype blocks (linkage disequilibrium co-
efficient (D’) . 0.94 for adjacent markers, D’ , 0.82 between
blocks), as well as one ‘isolated’ marker in moderate (D’ 5 0.7) link-
age disequilibrium with an adjacent marker (Supplementary Fig. 1).
Low linkage disequilibrium between markers that showed strong
association with the disease trait indicated that multiple variants
may independently confer disease susceptibility. We evaluated this
hypothesis statistically in a forward stepwise regression potentially
incorporating all the genotyped markers between 34.5 and 36.0 Mb
on chromosome 17. This identified three SNPs (rs7216389,
rs11650680 and rs3859192), which jointly showed strong association
to childhood asthma (P , 10212) and contributed statistically inde-
pendent significant effects (Supplementary Table 4). This result is
consistent with the possibility that more than one functional SNP
underlies the locus or (less likely given the SNP density across this
region) the presence of a single functional SNP in incomplete linkage
disequilibrium with the typed markers. Further fine-mapping studies
will be required to resolve these alternatives.
We further examined the impact of the chromosome 17q21 locus
on childhood asthma with the aid of 200 asthmatic cases and 2,120
non-asthmatic controls from within the cross-sectional study popu-
lation of ISAAC Phase II, recruited in Dresden and Munich. The
corresponding DNAs were genotyped for a series of nine markers
from across the locus that had shown evidence of association in the
GWA (Table 1). These showed the same trends as observed in the
GWA samples (odds ratios ranging from 1.52 to 1.11), and most were
significantly associated with disease with P , 0.001 (4 out of 9 mar-
kers) or P , 0.01 (5 out of 9 markers).
One chromosome 17q21 SNP associated with childhood asthma
in the GWA analysis (rs3894194, Table 1) had been previously
examined in 3,301 subjects from the UK 1958 birth cohort. The
genotype data for this marker were deposited for public use in the
database maintained by the investigators responsible for the cohort
study (http://www.b58cgene.sgul.ac.uk/). Although data were not
available for the other disease-associated chromosome 17q21 mar-
kers, we were able to confirm association to childhood asthma
with rs3894194, which is in linkage disequilibrium with the other
markers at the locus (linkage disequilibrium block 3 in Supple-
mentary Fig. 1). Restricting analyses to cohort members of
Caucasian ethnicity, we found that the 398 cases recalling ‘asthma
ever’ at age 42, showed a significant association (odds ratio, 1.21, 95%
confidence interval, 1.04–1.40, P 5 0.012). Ninety-three individuals
were reported to have ‘asthma attacks’ in the first seven years of life
(that is during 1958 to 1965), and these were strongly associated to
rs3894194 (odds ratio 5 1.68, 95% confidence interval, 1.25–2.26,
P 5 0.0005).
The disease-associated chromosome 17q21 markers had consist-
ent odds ratios and directions of association effects in the GWA



























Figure 2 | Genome-wide association of 317,447 SNPs and asthma in 994
asthmatic children and 1,243 non-asthmatic children. Position in the
genome, divided by chromosome, is depicted along the x axis. Strength of
association is shown on the y axis. The result for each individual marker is
depicted as a black circle. The genome-wide thresholds for 1% and 5% false
discovery rates (FDR) are shown as horizontal red lines. Numerous markers
on chromosome 17q21 show association to asthma above the 1% FDR
threshold in the region of maximum association.
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(Table 1), suggesting that we have identified a robust risk factor for
childhood asthma.
Variation in gene transcription is an important mechanism in
mediating susceptibility to asthma and other diseases, and the
transcript abundances of genes may be directly modified by poly-
morphisms in regulatory elements7,8. We therefore measured global
gene expression in EBVL from children in the MRC-A panel (Fig. 1).
These same subjects had been typed with the Illumina Sentrix
HumanHap300 and Sentrix Human-1 Genotyping BeadChips (Fig.
1). EBVLs represent the B-cell lineage, and are consequently of direct
relevance to asthma. Cells were harvested at log-phase in the first
growth after EBV transformation. Global transcript abundance was
measured with Affymetrix HG-U133 Plus 2.0 chips. We used quantile
normalization after Robust Multi-Array Average (RMA) to enforce
normality and reduce outlier leverage. A complete description of the
global results will be presented in another paper.
Expression data were available for 14 of 19 annotated genes in the
region from 35.0 to 35.5 Mb on chromosome 17 (that is, within
or near the 206 kb region of association on 17q21.1) (Fig. 3d). We
found that transcripts in one gene, ORMDL3, were strongly
(P , 10222 for rs7216389) and consistently positively associated to
exactly the same SNPs from the Illumina Sentrix HumanHap300
BeadChip as childhood asthma (Fig. 3c). The disease-associated mar-
kers accounted for 29.5% of the variance of expression. No other
markers were significantly correlated to ORMDL3 expression after
adjustment for genome-wide multiple testing. After accounting for
the effects of the disease-associated markers, the residual heritability
of the ORMDL3 expression was not significant (P 5 0.29 compared
to P 5 0.0009 before adjustment).
These findings suggested that the 17q21 disease-associated locus is
the principal genetic determinant of ORMDL3 expression. None of
the other transcripts from the region or elsewhere in the genome
showed a significant relationship to the disease-associated markers
in our data set. Despite the strength of these effects, the presence of
several SNPs independently associated to asthma nevertheless makes
it possible that ORMDL3 may not be the exclusive determinant of the
disease susceptibility at this locus.
In the subset of individuals for whom expression data are available,
the T nucleotide allele at rs7216389 (the marker most strongly assoc-
iated with disease in the combined GWA analysis) has a frequency of
62% amongst asthmatics compared to 52% in non-asthmatics
(P 5 0.005 in this sample). The additive effect of this allele corre-
sponds to a change of 0.78 standard deviation units in ORMDL3
expression (P , 10222). We saw the expected increase of ,0.064
standard deviation units in ORMDL3 expression among asthmatics,
but this was not significant given the sample size. Patterns of
ORMDL3 expression by genotype in asthmatics and non-asthmatics
are shown in Supplementary Fig. 2.
ORMDL3 is the third member of a novel class of genes of unknown
function that encode transmembrane proteins anchored in the
endoplasmic reticulum (ER)3. We examined multiple tissue com-
plementary (MTC) DNA panels by PCR with reverse transcription
(RT–PCR), and found ORMDL3 to be expressed in many tissues,
particularly liver and peripheral blood lymphocytes (Fig. 3g). The
SNPs showing the strongest association to asthma and ORMDL3
transcript abundances are contained within an island of linkage dis-
equilibrium between 35.2 and 35.4 Mb on chromosome 17q21
(Fig. 3b and 3c). The one-lod support unit for SNPs showing maxi-
mum association to ORMDL3 levels lies within the first intron of the
neighbouring GSDML gene. This non-coding sequence shows sig-
nificant homology between species (Fig. 3e and 3f), and contains an
element with high homology to the pro-inflammatory transcription
factor C/EBPb (transcription factor score, 86.8; http://www.cbrc.jp/
research/db/TFSEARCH.html).
Genomic regions other than the 17q21 locus did not contain









































































































































































































































Figure 3 | Association to asthma
and transcript abundances of
ORMDL3 on chromosome 17q21.
a, Mapping of association to asthma
on chromosome 17. b, Detail of
association to SNPs on
chromosome 17q21. c, Association
to ORMDL3 transcript abundance
with the same markers. A GOLD
plot22 of linkage disequilibrium
between markers is also shown, with
red indicating high linkage
disequilibrium and blue denoting
low. The central island of linkage
disequilibrium, which contains
maximum association to ORMDL3
and asthma, is contained within the
grey rectangle. d, Genes contained
within the associated interval.
e, Homology plot from the region of
maximum association. f, Sequence
homology from intron I of GSDML.
g, RT–PCR (34 cycles) of ORMDL3
cDNA from representative tissues
(Clontech).
LETTERS NATURE | Vol 448 | 26 July 2007
472
Nature  ©2007 Publishing Group
FDR threshold in either of the individual collections or the combined
samples. Several other loci (Supplementary Table 1) passed a less
stringent 5% FDR threshold after adjustment for population strati-
fication, indicating that other susceptibility loci for childhood
asthma could be present, perhaps having smaller effects than those
found on chromosome 17q21. These results will be explored in large
scale replication studies in multiple centres and population samples
(the GABRIEL project: http://www.gabriel-fp6.org/project).
METHODS SUMMARY
Children and their parents from the UK panels were administered a standard
questionnaire9 by a nurse or doctor. Asthma was defined as a positive response to
the question ‘‘Has your doctor ever told you that you have asthma?’’ Probands
had Step 3 asthma or worse according to British Thoracic Society guidelines10.
Siblings were included regardless of asthma status11. Asthma cases from the
MAGICS were diagnosed by a paediatric pulmonologist or allergologist on the
basis of clinical examination, history and objective tests of lung function. The
transformation of peripheral blood lymphocytes in all children in the MRC-A
panel was carried out by the ECACC (http://www.ecacc.org.uk). Microarray
hybridization of EBVL RNA to the U133 Plus 2.0 GeneChips (Affymetrix) was
under standard conditions. Whole-genome genotyping was carried out using
Illumina Sentrix Human-1 Genotyping BeadChip12and Sentrix HumanHap300
Genotyping BeadChips13 (Illumina, San Diego). Genotyping of additional mar-
kers was performed on an ABI7900HT Sequence Detection System using
TaqMan probes (Applied Biosystems, Foster City, California). German replica-
tion samples were genotyped using matrix-assisted laser desorption/ionization–
time of flight (http://www.sequenom.com)14. Logistic regression models with
robust sandwich estimation of the variance15 implemented in the Stata logit
function were used to detect association to asthma in the combined panels.
The TRANSMIT program16 was used to analyse nuclear family data (including
parental genotypes). The false-discovery rate (FDR) method5 was used to assess
the overall statistical significance of the genome-wide association results, and
FDR thresholds were calculated by applying the QVALUE (http://faculty.
washington.edu/,jstorey/qvalue/) package17. Gene expression data were nor-
malized with the RMA package18,19 to remove any technical or spurious back-
ground variation. An inverse normalization transformation step was also applied
to each trait to avoid any outliers. Association analysis was applied with Merlin
(FASTASSOC option)20, after probabilistically inferring missing genotypes21.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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Table 1 | Association of asthma and ORMDL3 to chromosome 17q21 in combined and replication panels





(P) [ORMDL3] Ref. allele Alt. allele Odds ratio Lower 95% CI Upper 95% CI 2log
10
(P) asthma
Marker MRC-A MAGICS Combined MRC-A
rs9303277 35.230 4.4 5.0 8.8 21.9 C T 1.41 1.14 1.76 2.8
rs11557467 35.282 4.6 5.2 9.1 22.5 G T 1.45 1.16 1.82 3.1
rs8067378 35.305 4.3 5.3 9.0 22.7
rs2290400 35.320 4.0 6.4 9.8 22.4 A G 1.47 1.18 1.82 3.2
rs7216389 35.323 4.3 6.4 10.0 22.4 T C 1.45 1.17 1.81 3.1
rs4795405 35.342 4.1 5.3 8.7 14.6 C T 1.52 1.20 1.89 3.6
rs8079416 35.346 2.4 6.5 8.2 10.9 C T 1.30 1.05 1.61 1.9
rs4795408 35.361 2.1 6.1 7.5 10.3 A G 1.25 1.01 1.54 1.4
rs3894194 35.376 1.9 6.6 7.7 11.0 T C 1.22 0.98 1.51 1.2
rs3859192 35.382 2.0 6.0 7.3 3.5 T C 1.11 0.89 1.37 0.4
SNPs are from the Illumina 300K panel. Results were calculated with logistic regression models. Association to ORMDL3 transcript abundance is shown for comparison and is based on the family
panel only. Replication results are shown for the ISAAC II population. CI, confidence interval; Ref., reference; Alt., alternative; eQTL, expression quantitative trait locus.
NATURE | Vol 448 | 26 July 2007 LETTERS
473
Nature  ©2007 Publishing Group
METHODS
Subjects. Children and their parents from the UK panels were recruited as part of
the MRC UK National family collection and were administered a standard
questionnaire (based on the American Thoracic Society and International
Study of Asthma and Allergies in Childhood (ISAAC) questionnaires9) by a
nurse practitioner or a doctor. Asthma was defined as a positive response to
the question ‘‘Has your doctor ever told you that you have asthma?’’ Probands
had Step 3 asthma or worse according to the British Thoracic Society guidelines
(high-dose inhaled steroids, or low-dose inhaled steroids and a long-acting
b-agonist)10. Siblings were included regardless of asthma status11. Asthma cases
from the Multicentre Asthma Genetics in Childhood Study (MAGICS) were
diagnosed by a paediatric pulmonologist or allergologist on the basis of clinical
examination, case history and objective tests of lung function. Asthmatics (mean
age 10.95 yr) were recruited from 7 centres located in Germany and Austria
(Wesel, Bochum Cologne, Freiberg, Munich, Feldkirch and Vienna), and as a
reference, 800 German children (mean age 9.62 yr) from Dresden (n 5 400) and
Munich (n 5 400) were randomly drawn from all German children with DNA
available in the cross sectional ISAAC Phase II study4. Further cases and controls
for replication were drawn from the German ISAAC population in which asthma
was diagnosed using standardized questionnaires and validated by lung function
and bronchial hyper-responsiveness testing4. All study methods were approved
by the appropriate ethics committees.
EBV. The transformation of the Peripheral Blood Lymphocytes (PBL) in all
children in the MRC-A panel was carried out by the ECACC (http://www.ecacc.
org.uk). Previously transformed cryo-preserved EBV cell lines were grown as
500 ml roller cultures. Once log phase had been obtained, cells were pelleted,
media discarded and a mixture of RLT buffer and b-mercaptoethanol added.
Pellets were vortexed to ensure thorough re-suspension, after which they were
frozen at 2 70uC and stored at 280 uC. RNA was extracted in batches after cell
homogenization using RNeasy Maxi Kits (Quiagen), and quality and quantity
assessed.
Microarray hybridization. RNA (10 mg) was used to synthesize double-stranded
cDNA using the One-cycle cDNA synthesis kit (Affymetrix). Using the cDNA as
a template, in vitro transcription of cRNA was carried out using the IVT kit
(Affymetrix), following the manufacturer’s protocol. A hybridization cocktail
was made according to protocol, using 15mg of labelled, fragmented cRNA, and
hybridized to U133 Plus 2.0 GeneChips (Affymetrix) for 16 h at 45 uC in a
rotating oven. GeneChips were washed and stained according to manufacturer’s
protocols and scanned on a high-resolution scanner (Affymetrix).
Genotyping. Whole-genome genotyping (WGGT) was carried out using
Illumina Sentrix Human-1 Genotyping BeadChip12 and Sentrix HumanHap300
Genotyping BeadChips13 (Illumina, San Diego), according to the manufacturer’s
instructions in a BeadLab with full automation at the Centre National de
Genotypage. All DNA samples were subjected to rigorous quality control to check
for fragmentation and amplification. Twenty microlitres of DNA at a concentra-
tion of 50 ngml21 was used for each array. DNA samples were tracked using a
Laboratory Information Management System. The HumanHap300 Genotyping
BeadChip was used with an Illumina LIMS, whereas the Sentrix Human-1
Genotyping BeadChip was tracked through the Illumina process by hand.
Groups of 24 samples were batched. Five percent of the samples were selected
from different batches, re-genotyped and the results compared to the original
data. No sample discrepancies were detected. Raw data were analysed using GTS
Image and extracted for statistical analysis. Genotyping of additional markers on
chromosome 17q21 was performed on an ABI7900HT Sequence Detection
System using TaqMan probes (Applied Biosystems, Foster City, California).
German replication samples were genotyped using matrix-assisted laser desorp-
tion/ionization time-of flight (MALDI-TOF) mass spectrometry (http://www.
sequenom.com)14. Primer extension products were analysed by a MassARRAY
mass spectrometer (http://www.bdal.de) and resulting mass spectra were analysed
using the SpectroTYPER RT 2.0 software.
Association testing. Tests of Hardy–Weinberg equilibrium were performed in
cases and controls using the genhw procedure (http://www.biostat-resources.
com/stata/) and Stata version 9.2, and SNPs showing Hardy–Weinberg disequi-
librium in controls (x2 . 25) were excluded. As the data comprised a mixture of
unrelated and related cases and controls, we used logistic regression models with
robust sandwich estimation of the variance15 as implemented in the Stata logit
function to model clustering of siblings’ genotypes. Simulations using the MRC-
A family structures (data available on request) confirmed that this method
appropriately controls the Type I error. Heterogeneity of association between
the two main strata (UK and Germany) was assessed by a weighted linear com-
bination test using the results of an additive-effects-only regression analysis
within each stratum. X-linked markers were analysed by fitting an additive-
effects-only logit model that equates the risks of male hemizygotes with female
homozygotes. The TRANSMIT program16 was used to analyse nuclear family
data (including parental genotypes), using the sandwich variance estimation
option to robustly incorporate information from multiple affected siblings;
confidence intervals for odds ratio estimates were computed as described. The
false-discovery rate (FDR) method5 was used to assess the overall statistical
significance of the genome-wide association results, taking into account the
multiple hypothesis testing implications inherent in the analysis of more than
300K SNPs. The FDR thresholds were calculated by applying the QVALUE
(http://faculty.washington.edu/,jstorey/qvalue/) software package17.
Association to transcript abundances. Data from the gene expression experi-
ment were normalized together using the RMA package18,19 to remove any
technical or spurious background variation. An inverse normalization trans-
formation step was also applied to each trait to avoid any outliers. Association
analysis was applied with Merlin (FASTASSOC option)20. We estimated an
additive effect for each SNP and tested its significance using a score test that
adjusts for familiality and takes into account uncertainty in the inference of
missing genotypes. In the absence of a positive genomic control test, we did
not adjust for stratification. We probabilistically inferred missing genotypes21
and adjusted for familiality, but not for linkage signal.
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